Shorter vs standard Tepezza for Thyroid Eye Disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study compares two different treatment plans for Thyroid Eye Disease (TED): the standard 8 infusions of Tepezza versus a shorter 4-infusion course. It aims to see if 4 treatments might work just as well and be safer, but only for people who already respond well after the first 4 doses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active Thyroid Eye Disease and are already being treated with Tepezza.
- You have shown clear improvement after your first 4 Tepezza treatments.
- You haven't used Tepezza or similar biologic medicines before for this condition.
- You do not have any hearing problems.
- You are able to give your permission to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This study tests if the drug teprotumumab can help with symptoms of thyroid eye disease, such as bulging eyes, pain, or double vision. It is for adults who are beneficiaries of the Department of Defense (DOD).
This trial tests a new version of an antibody treatment (teprotumumab) for people with active thyroid eye disease. It aims to reduce bulging and inflammation of the eyes, and you must have had symptoms for less than 9 months to join.
This trial tests whether teprotumumab (a monoclonal antibody medication) works better than high-dose steroids after urgent eye socket surgery in patients with thyroid eye disease affecting the optic nerve. The goal is to prevent vision loss and improve eye symptoms.
This trial tests a new drug called MHB018A for chronic thyroid eye disease (TED)—a condition where the eyes become inflamed and swollen due to thyroid problems. The study aims to see if this treatment can reduce eye inflammation and improve symptoms in people who have had TED for over a year.
This study offers continued treatment with MHB018A for patients with thyroid eye disease (swelling and bulging of the eyes from thyroid problems) who either didn't improve enough after 24 weeks of treatment or whose symptoms came back. The goal is to see if more treatment can help reduce eye bulging and other symptoms.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.